A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety,
pharmacokinetics, and pharmacodynamic effects of a single dose of the study drug or placebo
administered subcutaneously to patients with moderate-to-severe chronic kidney disease and
persistent inflammation.